Sponsor
Hunan Cancer Hospital
Clinical research sponsor
Clinical trials
51 shownPrecision Navigation to Improve Community Cancer Screening ParticipationNCT07676383 · lead sponsor · 2026-08-04
RECRUITINGFirmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaNCT07314216 · lead sponsor · 2026-06-22
RECRUITINGImmunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung CancerNCT06840704 · lead sponsor · 2025-02-25
RECRUITINGAnlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .NCT06734533 · lead sponsor · 2024-12-05
RECRUITINGUtidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant TherapyNCT06385990 · lead sponsor · 2024-03-29
RECRUITINGA Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCNCT05940532 · lead sponsor · 2023-06-14
RECRUITINGUTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain MetastasesNCT05535413 · lead sponsor · 2023-01-01
RECRUITINGReal-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.NCT06033287 · lead sponsor · 2023-01-01
RECRUITINGReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdNCT07073755 · lead sponsor · 2023-01-01
RECRUITINGEvaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer PatientsNCT05326295 · lead sponsor · 2019-03-01
RECRUITINGRucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedNCT07674368 · lead sponsor · 2026-07-10
NOT_YET_RECRUITINGA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNCT07163481 · lead sponsor · 2025-10-01
NOT_YET_RECRUITINGLorlatinib in ROS1+ NSCLC With Brain MetastasisNCT07083687 · lead sponsor · 2025-08-15
NOT_YET_RECRUITING18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast CancerNCT07859046 · lead sponsor · 2024-05-09
ENROLLING_BY_INVITATIONReal-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung CancerNCT06748495 · lead sponsor · 2024-02-05
ACTIVE_NOT_RECRUITINGA Real-world Study of Inetetamab for First-line Treatment of MBCNCT05980208 · lead sponsor · 2023-09-01
NOT_YET_RECRUITINGTucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast CancerNCT05633914 · lead sponsor · 2023-02-07
UNKNOWNReal-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast CancerNCT05561686 · lead sponsor · 2022-10-01
UNKNOWNAnlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsNCT05460481 · lead sponsor · 2022-06-12
UNKNOWNAnlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyNCT05001971 · lead sponsor · 2021-01-30
COMPLETEDSafety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerNCT05206656 · lead sponsor · 2020-10-09
COMPLETEDClinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaNCT04459078 · lead sponsor · 2020-08-26
UNKNOWNReal World Study on the Efficacy and Safety of Anti-HER2 TherapyNCT05367739 · lead sponsor · 2020-06-01
COMPLETEDPyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast CancerNCT04407988 · lead sponsor · 2019-11-06
UNKNOWNAssessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLCNCT03994744 · lead sponsor · 2019-08-20
UNKNOWNClinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerNCT04239443 · lead sponsor · 2019-01-30
UNKNOWNAnlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung CancerNCT03624309 · lead sponsor · 2018-10-15
UNKNOWNCirculating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast CancerNCT05427617 · lead sponsor · 2016-12-01
COMPLETEDClinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast CancerNCT05079074 · lead sponsor · 2016-12-01
COMPLETEDA Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerNCT07544056 · collaborator · 2026-06-04
RECRUITINGHypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based ReconstructionNCT06830083 · collaborator · 2025-01-30
RECRUITINGStudy on Human Bioequivalence of Triprerelin Acetate for InjectionNCT06683066 · collaborator · 2024-12-04
RECRUITINGEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesNCT06440954 · collaborator · 2024-05-01
RECRUITINGPatient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap ReconstructionNCT05512286 · collaborator · 2022-08-25
RECRUITINGUtidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerNCT05430399 · collaborator · 2022-06-21
RECRUITINGExploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)NCT05598528 · collaborator · 2021-09-28
RECRUITINGThe Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)NCT05113017 · collaborator · 2021-07-01
RECRUITINGSurgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNCT07687225 · collaborator · 2026-09-01
NOT_YET_RECRUITINGA Prospective, Non-interventional Cohort Study of Subsolid Pulmonary NodulesNCT06458673 · collaborator · 2024-12-01
NOT_YET_RECRUITINGLorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNCT06682884 · collaborator · 2024-11-15
NOT_YET_RECRUITINGLiposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung CancerNCT06462105 · collaborator · 2024-07-05
NOT_YET_RECRUITINGStudy of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNCT05812534 · collaborator · 2023-12-01
UNKNOWNSurufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNCT05882630 · collaborator · 2023-06-01
UNKNOWNTGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)NCT05955391 · collaborator · 2023-01-18
ACTIVE_NOT_RECRUITINGPhase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNCT05461690 · collaborator · 2022-09-01
UNKNOWNctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLCNCT05198154 · collaborator · 2022-01-24
ACTIVE_NOT_RECRUITINGBioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese PatientsNCT05273944 · collaborator · 2021-07-28
UNKNOWNA Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)NCT04636762 · collaborator · 2020-06-01
COMPLETEDPhase I Study of BEBT-209 in Women With Advanced Breast CancerNCT06047184 · collaborator · 2019-07-15
COMPLETEDEfficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast CancerNCT03351062 · collaborator · 2017-11-01
UNKNOWNSafety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast CancerNCT04103853 · collaborator · 2017-09-06
COMPLETEDSponsor roles
lead sponsor29
collaborator22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.